Accordingly, the anti-PD-L1/TIGIT combination is the most effective strategy for blocking the growth of cSCCs that contain epithelial, hybrid E/M, and mesenchymal cancer cells through stimulation of both CTLs and NK cells, highlighting that mixed cSCCs should be treated with combined therapies to address both cancer cell components. The gene discussed is TIGIT; the disease is cancer.